Real-World study reveals how breast cancer drug palbociclib is used in israel
NCT ID NCT04671615
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib (Ibrance) as part of their treatment. Researchers tracked how the drug was used in everyday practice, including doses, combinations with other treatments, and how long patients stayed on therapy. The goal was to understand real-world treatment patterns and outcomes over about 3.5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib (Ibrance)
What this could lead to
If successful, this study could help doctors understand how palbociclib is actually used in real-world settings, potentially improving treatment guidelines for metastatic breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, 4672509, Israel